Mariner
TVTX icon

Mariner’s Travere Therapeutics TVTX Stock Holding History

Mariner’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Sell
8,358
-2,489
-23% -$110K ﹤0.01% 2495
2026
Q1 		$322K Sell
10,847
-7,372
-40% -$220K ﹤0.01% 2804
2025
Q4 		$696K Buy
18,219
+9,359
+106% +$304K ﹤0.01% 2218
2025
Q3 		$212K Sell
8,860
-2,268
-20% -$42.6K ﹤0.01% 3125
2025
Q2 		$165K Sell
11,128
-636
-5% -$10.5K ﹤0.01% 3113
2025
Q1 		$211K Buy
11,764
+557
+5% +$11.3K ﹤0.01% 2958
2024
Q4 		$195K Buy
11,207
+111
+1% +$1.96K ﹤0.01% 3013
2024
Q3 		$155K Buy
+11,096
New +$116K ﹤0.01% 2997

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mariner's TVTX Position: Q2 2026 in Review

Mariner reduced its Travere Therapeutics (TVTX) stake by 23% in Q2 2026, selling an estimated $110K and leaving 8,358 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

Mariner first reported a position in TVTX in Q3 2024 and has held it in 8 quarters since. The position peaked at $696K in Q4 2025. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Mariner held 8,358 shares of Travere Therapeutics worth $475K as of Q2 2026.
  • Mariner sold 2,489 Travere Therapeutics shares in Q2 2026, an estimated $110K.
  • Travere Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2495 holding.
  • Mariner first reported a position in Travere Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Mariner's Travere Therapeutics position peaked at $696K in Q4 2025.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.